We have updated our Privacy Policy. You can find out more here.
For Equine Vets Everywhere

VMD Medicines Update - November 2021

News Medicines
21 Dec 2021 BEVA

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.

New marketing authorisations

Table 1 shows the new marketing authorisations for November 2021.

TABLE 1: New marketing authorisations in November 2021

New Marketing Authorisations

Product name and target species

Active substance

Authorisation Holder, territory, and distribution category

Therapeutic group


Food animals

Calcibel Forte, 380/60/50 mg/ml solution for infusion for horses, cattle, sheep, goats and pigs

Magnesium chloride hexahydrate, Boric acid, Calcium gluconate monohydrate

Bela-Pharm GmbH & Co. KG




See the VMD’s Product Information Database (www.gov.uk/check-animal-medicine-licensed) for more information on each of these products. This includes separate links for the authorisation territories of Great Britain and Northern Ireland.

Please note, there may be a delay between the issuing of a marketing authorisation and the product being placed on the market.

Changes to authorisations most relevant to vets

The changes to authorisations most relevant to vets can be found below. Each product listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics sections have been revised/changed.

All entries can be found on the VMD’s Product Information Database here.

Changes to the SPC, labels and leaflets may change how the medicines should be used. There may be a delay between these changes being authorised to implementation on product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

Equipulmin 25 micrograms/ml syrup for horses 

CP Pharma Handelsgesellschaft mbH       Authorised in GB & NI    POM-V

Section 4.7: Since clenbuterol hydrochloride is excreted in milk, the product should not be used in lactating mares with foals up to the age of two months.

Section 4.8: Enhanced effects including more frequent adverse effects when used concomitantly with ß2 sympathomimetic drugs, anticholinergic substances, and methylxanthines.  Increased risk of arrhythmias when administered concomitantly with digitalis glycosides.

Section 4.9: (0.7 micrograms clenbuterol per kg bodyweight). Duration of treatment: 10-14 days in acute or subacute conditions, over a longer period of time in chronic cases. If signs improve significantly, the dosage can be reduced by half after approximately 10 days.

For more information, contact the VMD at postmaster@vmd.gov.uk